ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706
Multiple sclerosis progression: time for a new mechanism-driven frameworkTanja Kuhlmann, Emmaunelle Waubant, Marcello Moccia et al.|The Lancet Neurology|2022Cited by 624
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Bernhard Hemmer, Friedemann Paul et al.|The Lancet Neurology|2021Cited by 518
<scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|European Journal of Neurology|2018Cited by 222
Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple SclerosisJannis Müller, Ludwig Kappos, Alessandro Cagol et al.|JAMA Neurology|2023Cited by 194